Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Biometrical Journal. Biometrische Zeitschrift|February 25, 2024
Nonparametric analysis of delayed treatment effects using single-crossing constraintsNicholas C Henderson, Kijoeng Nam, Dai FengJournal of Biopharmaceutical Statistics|March 28, 2017
Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety SurveillanceKijoeng Nam, Nicholas C Henderson, Patricia Rohan, et al.Future Oncology (London, England)|March 13, 2020
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBCAshish M Kamat, Neal Shore, Noah Hahn, et al.The Lancet. Oncology|May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.The Lancet. Oncology|May 29, 2021
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al.Pageof 1